IL131447A0 - Combined tumor supressor gene therapy and chemotherapy in the treatment of neoplasms - Google Patents

Combined tumor supressor gene therapy and chemotherapy in the treatment of neoplasms

Info

Publication number
IL131447A0
IL131447A0 IL13144798A IL13144798A IL131447A0 IL 131447 A0 IL131447 A0 IL 131447A0 IL 13144798 A IL13144798 A IL 13144798A IL 13144798 A IL13144798 A IL 13144798A IL 131447 A0 IL131447 A0 IL 131447A0
Authority
IL
Israel
Prior art keywords
treatment
neoplasms
chemotherapy
gene therapy
tumor suppressor
Prior art date
Application number
IL13144798A
Other languages
English (en)
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of IL131447A0 publication Critical patent/IL131447A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrotherapy Devices (AREA)
IL13144798A 1997-02-18 1998-02-17 Combined tumor supressor gene therapy and chemotherapy in the treatment of neoplasms IL131447A0 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US80168197A 1997-02-18 1997-02-18
US80176597A 1997-02-18 1997-02-18
US80128597A 1997-02-18 1997-02-18
US80175597A 1997-02-18 1997-02-18
US3806597P 1997-02-18 1997-02-18
US4783497P 1997-05-28 1997-05-28
PCT/US1998/003514 WO1998035554A2 (fr) 1997-02-18 1998-02-17 Combinaison therapie genique suppressive de tumeurs - chimiotherapie utilisee dans le traitement de neoplasmes

Publications (1)

Publication Number Publication Date
IL131447A0 true IL131447A0 (en) 2001-01-28

Family

ID=27556335

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13144798A IL131447A0 (en) 1997-02-18 1998-02-17 Combined tumor supressor gene therapy and chemotherapy in the treatment of neoplasms
IL195605A IL195605A0 (en) 1997-02-18 2008-11-30 Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL195605A IL195605A0 (en) 1997-02-18 2008-11-30 Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms

Country Status (19)

Country Link
EP (1) EP0969720B1 (fr)
JP (1) JP2001511815A (fr)
KR (2) KR100688409B1 (fr)
CN (1) CN1248731C (fr)
AT (1) ATE361668T1 (fr)
AU (1) AU737621B2 (fr)
BR (1) BR9807418A (fr)
CA (1) CA2282683A1 (fr)
CZ (1) CZ298488B6 (fr)
DE (1) DE69837754T2 (fr)
ES (1) ES2287974T3 (fr)
HK (1) HK1026579A1 (fr)
HU (1) HUP0004326A3 (fr)
IL (2) IL131447A0 (fr)
NO (1) NO993943L (fr)
NZ (1) NZ337283A (fr)
PL (1) PL193767B1 (fr)
SK (1) SK285969B6 (fr)
WO (1) WO1998035554A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US7163925B1 (en) 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
JPH11510380A (ja) 1995-07-17 1999-09-14 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ｐ１６発現構築物および癌治療におけるその適用
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
ATE348155T1 (de) 1996-11-20 2007-01-15 Introgen Therapeutics Inc Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
JP4502503B2 (ja) * 1997-12-22 2010-07-14 シェーリング コーポレイション 増殖性の疾患を処置するためのベンゾシクロヘプタピリジン化合物および抗腫瘍剤の組合せ
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
AU762986B2 (en) * 1998-04-22 2003-07-10 Inex Pharmaceuticals Corporation Combination therapy using nucleic acids and conventional drugs
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
WO2000056351A2 (fr) * 1999-03-19 2000-09-28 Schering Corporation Association therapeutique de gemcitabine et d'un gene suppresseur de tumeur aux fins du traitement de neoplasmes
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US6911200B2 (en) 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
US7048920B2 (en) 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
ATE481640T1 (de) * 2000-11-27 2010-10-15 Minerva Biotechnologies Corp Diagnostika, drogenscreening und behandlung für krebs
EP1340498A1 (fr) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Utilisation d'épothilones dans le traitement de maladies du cerveau associées aux processus de prolifération
US7364727B2 (en) 2002-07-22 2008-04-29 Cell Genesys, Inc. Metastatic colon cancer specific promoter and uses thereof
CA2548220A1 (fr) 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Utilisation de mda-7 pour inhiber des organismes infectieux pathogenes
JPWO2005061007A1 (ja) * 2003-12-24 2007-07-12 学校法人 聖マリアンナ医科大学 癌の抑制方法
CN1909927A (zh) * 2003-12-24 2007-02-07 株式会社洛科摩基因 抑制癌的方法
KR20070104339A (ko) 2004-11-03 2007-10-25 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터의 생산과 정제를 위한 신규한 방법
JP6895890B2 (ja) 2015-02-10 2021-06-30 ミネルバ バイオテクノロジーズ コーポレーション ヒト化抗ｍｕｃ１＊ 抗体
CN106692989A (zh) * 2017-03-07 2017-05-24 大连民族大学 一种药物脂质体/p53基因复合物及其制备方法和应用
CN109200295A (zh) * 2018-10-08 2019-01-15 蚌埠医学院 一种用于治疗卵巢癌的药物组合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
SG43768A1 (en) * 1993-10-15 1997-11-14 Schering Corp Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative dieases
DK1019392T3 (da) * 1995-12-22 2006-03-20 Schering Corp Tricykliske amider anvendelige til inhibering af G-proteinfunktion og til behandling af proliferative sygdomme

Also Published As

Publication number Publication date
ES2287974T3 (es) 2007-12-16
HUP0004326A3 (en) 2003-07-28
HK1026579A1 (en) 2000-12-22
IL195605A0 (en) 2011-08-01
SK285969B6 (sk) 2007-12-06
PL335334A1 (en) 2000-04-25
CN1248731C (zh) 2006-04-05
KR20050113287A (ko) 2005-12-01
PL193767B1 (pl) 2007-03-30
NO993943D0 (no) 1999-08-17
KR20000071185A (ko) 2000-11-25
EP0969720A2 (fr) 2000-01-12
NO993943L (no) 1999-10-15
CA2282683A1 (fr) 1998-08-20
EP0969720A4 (fr) 2004-05-12
NZ337283A (en) 2001-02-23
JP2001511815A (ja) 2001-08-14
ATE361668T1 (de) 2007-06-15
BR9807418A (pt) 2002-01-22
AU6438098A (en) 1998-09-08
CN1252689A (zh) 2000-05-10
EP0969720B1 (fr) 2007-05-09
WO1998035554A3 (fr) 1998-11-26
WO1998035554A2 (fr) 1998-08-20
SK112299A3 (en) 2000-12-11
CZ298488B6 (cs) 2007-10-17
DE69837754D1 (de) 2007-06-21
CZ293399A3 (cs) 2000-03-15
KR100620939B1 (ko) 2006-09-06
HUP0004326A2 (hu) 2001-02-28
DE69837754T2 (de) 2008-02-07
KR100688409B1 (ko) 2007-03-02
AU737621B2 (en) 2001-08-23

Similar Documents

Publication Publication Date Title
IL195605A0 (en) Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
EP1004022A4 (fr) Methodes et compositions pour surmonter la resistance a une therapie biologique et a une chimiotherapie
EP1167972A3 (fr) Agents thérapeutiques catalysés par les enzymes
TR199902053T2 (xx) Prostat kanserinin immunoterapisine y�nelik bile�ikler ve bunlar�n kullan�lmas�na matuf metodlar.
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
DE69837529D1 (de) Proteinmarker für lungenkrebs und deren verwendung
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
WO2000028090A3 (fr) Essais diagnostiques du cancer
MX9706109A (es) Moleculas de adn, preparacion y utilizacion en terapia genica.
AU7013401A (en) Methods for enhancing antibody-induced cell lysis and treating cancer
MY138257A (en) Compositions and methods for enhancing delivery of therapeutic agents to cells
IL128872A0 (en) TNF-beta-like protein for treating prostate cancer and related nucleic acid molecules pharmaceutical compositions and methods
WO2003008578A3 (fr) Agents reactifs et procedes d'identification de genes cibles dans le traitement du cancer
AU6249098A (en) Method of treating cancer using alkylglycerols in conjunction with chemotherapy
EP0950062A4 (fr) Marqueur proteique pour cancer de l'oesophage
BR0012301A (pt) Inibidores de crescimento de células epiteliais
WO2000056351A3 (fr) Association therapeutique de gemcitabine et d'un gene suppresseur de tumeur aux fins du traitement de neoplasmes
WO2000036420A3 (fr) Expression differentielle dans le cas du cancer primaire du sein
WO2001034634A8 (fr) Molecules suppresseurs de tumeur et procedes d'utilisation
GB9723824D0 (en) Cytostatic agents
EP1240922A3 (fr) Méthodes et composés de combattre la résistance à la thérapie biologique et chimique
CO5080825A1 (es) Sistema de terapia con genes suicidas para el tratamiento de tumores cerebrales
MX9802005A (es) Moleculas de adn circular con origen de replicacion condicional, su proceso de preparacion y su utilizacion en terapia genica.